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Background: It is important to identify cardiovascular diseases in patients at high risk. To include genetics into
routine cardiological patients has therefore been discussed recently.
We wanted to evaluate the association between high-molecular weight adiponectin and cardiovascular risk, and
secondly in the same population evaluate if specific genotype differences regarding risk could be observed, and
thirdly if gender differences could be seen.
Method: Four hundred seventy-six elderly participants recruited from a rural community were included. All
participants underwent a clinical examination, echocardiography, and blood sampling and the single nucleotide
polymorphism (SNP) (rs266729) of adiponectin was analysed. Follow-up time was 6.7 years.
Results: Those with high serum concentration of adiponectin had a more 2 fold increased cardiovascular risk, and
it might be that females exhibits even higher risk where a more than 5 fold increased risk could be seen. The result
could be demonstrated even in a multivariate model adjusting for well-known clinical risk factors. However, as the
sample size was small the gender differences should be interpreted with caution. In the genotype evaluation the
C/C carriers of the female group had a more than 9-fold increased risk of cardiovascular mortality, however the
confidence interval was wide. Such genotype difference could not be found in the male group.
Conclusion: High level of adiponectin was associated with increased cardiovascular risk. Also a gender difference in
the genotype evaluation could be seen where the C/C carriers obtained higher risk in the female group but not in
the male group. Thus, in order to identify patients at risk early, genetic analyses may add to the armamentarium
used in the clinical routine. However, information should be regarded as hypothesis generating as the sample
size was small and should stimulate further research in individualized cardiovascular prevention and treatment.
Keywords: Genotypes, Gender, PrognosisBackground
Adiponectin is a peptide hormone and secreted from
adipose tissue. It has a multitude of actions in the
body, and has been shown to have insulin-sensitizing
effects [1], anti-atherosclerotic effects [2], but also
anti-inflammatory effects [3]. In obese patients the
circulating levels of adiponectin are reduced [4]. Interest-
ing, but contradictory data of the role of adiponectin in
the cardiovascular area have been published. Li et al., re-
port that in patients with coronary artery disease, a low
plasma concentration of adiponectin is associated with* Correspondence: urban.alehagen@liu.se
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study of more than 18,200 males Pischon et al. reported
that a high plasma concentration of adiponectin was asso-
ciated with a lower risk of myocardial infarction in persons
without coronary artery disease [6]. However, Hascoet
et al. report a higher cardiovascular risk in those with a
high serum concentration of adiponectin from a popula-
tion with established coronary artery disease, but also in
controls [7]. Also, the Health ABC Study, Poehls et al.
reported that in elderly healthy persons a higher con-
centration of adiponectin was associated with higher
cardiovascular risk [8], and in elderly men without
diagnosed cardiovascular disease Wannamethee et al.
reported a higher cardiovascular risk in those with high
plasma concentration of adiponectin [9]. In an effort toss article distributed under the terms of the Creative Commons Attribution
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meta-analysis including 14 different studies a strong as-
sociation between high concentration of adiponectin
and all-cause mortality, but also from eleven different
studies in a meta-analysis a strong association between
high concentration of adiponectin and cardiovascular
mortality [10]. From a study of almost 700 female pa-
tients Mackey et al. could report an association be-
tween high concentration of adiponectin and coronary
heart disease in those with diabetes, but not among
those without diabetes [11]. In elderly persons with
atrial fibrillation, a higher concentration of adiponectin
was reported by Macheret et al. in a study of more than
3000 individuals [12]. In an interesting study performed
in dogs, Damoiseaux C et al. demonstrated a higher
adiponectin concentration in dogs with dilated cardio-
myopathy, compared to healthy dogs of the corre-
sponding age [13]. From Portugal, Fontes-Carvalho
et al. reported that females, but not males with high
concentration of adiponectin had increased risk for dia-
stolic impairment of the heart [14]. From three surveys
of healthy persons Karakas et al. could not report any
associations between serum level of adiponectin and
risk coronary heart disease [15]. Thus a complex pic-
ture is reported regarding a possible association be-
tween adiponectin and cardiovascular risk. However, in
the vast majority of reports total adiponectin is ana-
lyzed, where only a minority of articles report on high-
molecular-weight adiponectin, the biologically active
part [16].
From the literature it is also evident that different geno-
types of adiponectin could associated with cardiovascular
risk. However, various researchers have investigated the
role of the adiponectin gene in the risk of coronary artery
disease with inconsistent results [17–19], and different
single nucleotide polymorphisms (SNPs) of adiponectin
have different associations with coronary artery disease
risk [20–22]. The SNP rs266729 of adiponectin has been
reported with increased risk of coronary artery disease in
some reports [17, 23, 24], whereas Cheung et al. could not
report any association between rs266729 and risk of cor-
onary artery disease either in males nor in females [25].
Pileggi et al. reported that that the G allele of rs266729
was associated with increased risk of heart failure as
evaluated from a population of more than 2300 Italian
participants of which half had heart failure [26]. Thus,
there is evidence that rs266729 could give prognostic
cardiovascular information based on the literature.
The primary aim of this study was therefore to
evaluate a possible association of cardiovascular death
with expression of high molecular weight of adiponec-
tin and rs266729 gene polymorphism. The secondary
aim was to evaluate if the associations are gender
specific.Methods
Patient population
The study population consisted of 476 apparently
healthy individuals (men: 242; females: 234) with a
mean age of 77.0 years (range:18 years) living in a rural
municipality in the south-east of Sweden and invited to
participate in this project. They were all part of a longi-
tudinal epidemiological study focusing on cardiovascu-
lar risk factors [27]. All the participants in that study
were invited to participate in the present sub-study
conducted from 13th January 2003 through 18th June
2005. All participants underwent a clinical examination,
ECG recording, and Doppler-echocardiography, and
blood samples were collected. New York Heart Associ-
ation (NYHA) functional class classification (The
NYHA functional class grades how a patient with heart
disease experiences symptoms of tiredness, breathless-
ness or chest pain and is graded from I-IV, where IV is
symptoms experienced while at rest) was evaluated by
the including physician based on the patient informa-
tion. All participants gave their informed consent, and
the study was conducted in accordance with the Declar-
ation of Helsinki principles. The study protocol was ap-
proved by the Regional Ethical Review Board of Linköping,
Sweden (Dnr 95044). The mortality information was
obtained from the National Board of Health and Welfare
in Sweden, which registers all deaths, or from autopsy
reports.
Morbidity
Diabetes mellitus was defined as a previous diagnosis
with on-going treatment, or a blood glucose ≥ 7 mmol/L.
Hypertension was defined as a previous diagnosis with
on-going treatment or a blood pressure ≥ 140/90 mmHg
at rest. Ischemic heart disease was defined as a history
of angina pectoris/myocardial infarction or ECG-verified
myocardial infarction. Heart failure was defined as a pre-
vious diagnosis with on-going treatment, or symptoms/
signs of heart failure and objective demonstration of re-
duced cardiac function in terms of impaired cardiac
function on echocardiography, or increased plasma con-
centration of proBNP 1–76.
Echocardiography
Echocardiography examinations were performed on (Accu-
son XP-128c) with the patients in a supine left position.
Values for systolic function expressed as left ventricular
ejection fraction (EF), were categorized into four classes
with interclass limits 30 %, 40 % and 50 %. Normal systolic
function was defined as EF ≥ 50 %.
Biochemical analyses
All blood samples were collected in pre-chilled plastic
Vacutainer tubes (Terumo EDTA K-3, Terumo Europe
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at rest in a supine position. Plasma was prepared by cen-
trifugation at 3000 g for 10 min at 4 °C. All samples
were stored at—70 °C until analysis, and none of the
samples were thawed more than twice.
ProBNP 1–76 (NT-proBNP) was measured using the
Elecsys 2010 platform (Roche Diagnostics, Mannheim,
Germany). The total coefficient of variation was 4.8 % at 26
pmol/L and 2.1 % at 503 pmol/L (n = 70) at our laboratory.
HMW-Adiponectin
High molecular weight form of adiponectin concentra-
tions were measured in serum using Quantikine ELISA
kit according to the manufacturer’s instructions (R&D
Systems, Abingdon, United Kingdom). In brief, serum
samples were diluted 1:100 and added to the mouse
monoclonal capture antibody precoated wells for three
hours. After washing, high molecular weight conjugate
was added for one hour, which was followed by washing,
and thereafter substrate solution was added for 30 min.
After addition of stop solution, optical density of each well
was determined using a microplate reader set to 450 nm
with wavelength correlation set to 540 nm.
Genotype determination
Genomic DNA was isolated from peripheral blood using
QIAmp DNA Mini Kit (QIAGEN, Hilden, Germany),
following the manufacturer’s instructions. The 7500 Fast
Real-Time PCR system (Applied Biosystems, CA, USA)
was used for analysis of adiponectin (rs266729) using a
TaqMan SNP genotyping assay mixed with TaqMan
Universal PCR Master mix II (Applied Biosystems).Table 1 Basal characteristics of the total study population and divid
Variables Total population
N 476
Age, mean (SD) 77.0 (3.4)
BMI, (SD) 27.2 (4.3)
IHD, n (%) 105 (22.1)
Hypertension, n (%) 359 (75.4)
ACEI/ARB, n (%) 125 (26.3)
Hb < 120 g/L, n (%) 51 (10.7)
Beta blockers, n (%) 168 (35.3)
b-glucose, mmol/L, mean, (SD) 4.6 (1.3)
HDL, mmol/L mean, (SD) 1.5 (0.4)
eGFR < 60 mL/min, n (%) 233 (48.9)
CRP, mg/L, mean (SD) 11.0 (5.1)
EF < 40 %, n (%) 36 (7.6)
NT-proBNP ng/L, mean, (SD) 188 (319)
Adiponectin pg/mL, mean, (SD) 6263 (4690)
Notes: ACEI/ARB: Angiotensin converting enzyme inhibitor/Angiotensin receptor blo
Estimated glomerular filtration rate; HDL; High density lipoproteins; IHD: Ischemic hStatistical methods
Descriptive data are presented as percentages or mean
and SD. Comparative analyses were performed using the
Student unpaired two-sided T-test, whereas the chi-
square test was used for discrete variables. One-way ana-
lysis of variance (ANOVA) followed by Bonferroni’s
post-hoc test were used to compare values between the
different genotypes. Both univariate and multivariate
Cox proportional hazard regression analyses as well as a
Kaplan-Meier analysis were used to analyse and illustrate
the risk of mortality during the follow-up period. The
covariates that were adjusted for in the multivariate
model were: Age, Hypertension, Ischemic heart disease,
Body mass index, C-reactive protein, b-glucose, High
density lipoprotein, Estimated glomerular filtration
rate < 60 mL/min, Hemoglobin < 120 g/L, Ejection frac-
tion < 40 % and N-terminal fragment of proBNP 4th quar-
tile. Both all-cause mortality and cardiovascular mortality
were analysed. Censored patients were patients who were
still alive at end of the study period or who had died of
other causes than cardiovascular disease. Completed pa-
tients comprised those who had died due to cardiovascular
disease.
A P-value < 0.05 was considered statistically significant.
All data were analysed using standard software packages
(Statistica v. 12.0, Statsoft Inc, Tulsa, OK, USA).
Results
The basal characteristics of the total study population
are presented in Table 1. Almost equal numbers of males
and females were included (242 vs. 234). In the total
study population, 359/476 (75.4 %) of the participantsed into genders
Males Females p-value
242 234
77.0 (3.2) 77.0 (3.7)
26.7 (3.3) 27.6 (5.1) 0.02
63 (26.0) 42 (17.9) 0.03
174 (71.9) 185 (79.1) 0.003
64 (26.4) 61 (26.1) 0.93
16 (6.6) 35 (15.0) 0.003
90 (37.2) 78 (33.3) 0.38
4.5 (1.2) 4.6 (1.4) 0.57
1.3 (0.3) 1.6 (0.4) <0.0001
116 (47.9) 117 (50.0) 0.65
11.0 (5.0) 11.0 (5.3) 0.68
27 (11.2) 9 (3.8) 0.003
201 (395) 174 (200) 0.37
4829 (3391) 7884 (5387) <0.0001
cker; BMI: Body mass index; CRP: C-reactive protein; EF: Ejection fraction; eGRF:
eart disease; NT-proBNP: N-terminal fragment of proBNP
Alehagen et al. BMC Medical Genetics  (2015) 16:37 Page 4 of 8had hypertension, a significant greater part was females
(79.1 % vs. 71.9 %). In the total study population 105/476
(22.1 %) had ischemic heart disease, and 10.7 % had anemia,
defined as Hb > 120 g/L, where the female group was sig-
nificantly overrepresented in comparison to the male group
(15.0 % vs. 6.6 %). Significantly more males had impaired
cardiac systolic function compared to the females (11.2 %
vs. 3.8 %). The median follow-up time for the total popula-
tion was 80 months (6.7 years), and during this time 106
all-cause and 62 cardiovascular deaths were registered.
High-weight-molecular (HWM) adiponectin
The biologically active part of adiponectin, HWM-
adiponectin was evaluated in the total study population.
From the gender characteristics it could be seen that the
female group had clearly higher concentration of adiponec-
tin (mean: 7884 pg/mL vs. 4829 pg/mL; t = 6.51; p <
0.0001). The four quartiles of HMW-adiponectin (1st quar-
tile: < 3875 pg/mL; 2nd quartile: 3875-6630 pg/mL; 3rd
quartile; 3876-8047 pg/mL; 4th quartile; >8047 pg/mL)
were evaluated according to cardiovascular risk.
Adiponectin and cardiovascular mortality
In a univariate cox proportional hazard regression evalu-
ating the prognostic information on cardiovascular mor-
tality, it could be seen that those with high concentration
of adiponectin had a significant increased risk (HR: 2.58
95 % CI 1.30–5.14; p = 0.007). This result persisted when
evaluated adiponectin in a multivariate model including
NT-proBNP, one of the most well-known biomarkers to
evaluate cardiovascular risk (HR: 2.35 95 % CI 1.15–4.82;
p = 0.02) (Table 2). A gender difference could be noted
in the univariate Cox model (males: hazard ratio:Table 2 Cox proportional hazard regression illustrating the risk of ca
population having a high plasma concentration of adiponectin
Variables Total population
Hazard ratio 95 % CI p-value
Age 1.12 1.03–1.21 0.005
Hypertension 1.28 0.69–2.39 0.43
IHD 1.03 0.56–1.92 0.92
BMI 0.99 0.92–1.05 0.69
CRP 0.99 0.93–1.05 0.79
b-glucose 1.14 0.97–1.35 0.11
s-HDL 0.61 0.29–1.28 0.19
eGFR < 60 mL/min 0.72 0.34–1.55 0.40
Hb < 120 g/L 1.13 0.54–2.34 0.75
EF < 40 % 1.74 0.81–3.74 0.16
NT-proBNP Q4 (>197 ng/L) 2.54 1.21–5.34 0.01
Adiponectin Q4 (>12800 pg/mL) 2.35 1.15–4.82 0.02
Notes: BMI: Body mass index; CI: Confidence interval: CRP: C-reactive protein; EF: Eje
lipoproteins; NT-proBNP: N-terminal fragment of proBNP; Q: Quartile2.16; 95 % CI 0.52–9.07; p = 0.29 versus females: hazard
ratio: 5.32; 95 % CI 1.93–14.71; p = 0.001). The gender
difference previously described persisted, and in an inter-
actions analysis a significant (p < 0.0001) interaction
could be demonstrated. However, the limited sample size
should be noted, and the interpretation should therefore
be performed with caution
Genotypes
The different genotypes C/C, C/G and G/G of rs266729
were analysed in the same population as evaluated above.
In the total study population the C/C genotype was the
most common in both the male and the female group
(Table 3), followed by the C/G genotype. No gender differ-
ence could be seen regarding the distribution of genotypes
of the rs266729.
Genotypes of rs266729 and cardiovascular mortality
In the total study population no increased cardiovascular
mortality risk could be seen comparing the C/C carriers
versus the C/G or the G/G carriers (HR: 1.54 95 % CI
0.91–2.61; p = 0.11) (Table 4). However, evaluating the dif-
ferent genders the female group exhibited in a univariate
Cox proportional hazard regression analysis a highly in-
creased risk of cardiovascular mortality in the rs266729 C/C
genotype compared to the C/G or G/G genotypes (HR:
6.48; 95 % CI 1.49–28.18; p = 0.01), although the confidence
interval was wide. Performing a multivariate analysis of the
Cox proportional hazard regression, where risk of cardiovas-
cular mortality was evaluated, a highly significant increased
risk was demonstrated (HR: 9.35; 95 % CI 1.99–43.91;
p = 0.005), even in competition with clinical variables
influencing cardiac risk (Table 4). Again, the confidencerdiovascular mortality during 6.7 years of follow-up of the study
Males Females
Hazard ratio 95 % CI p-value Hazard ratio 95 % CI p-value
1.17 1.06–1.30 0.002 1.10 0.93–1.30 0.26
1.38 0.68–2.81 0.37 1.05 0.27–4,23 0.94
0.72 0.34–1.54 0.40 1.57 0.47–5.22 0.46
0.93 0.83–1.03 0.17 1.12 1.00–1.24 0.04
0.99 0.94–1.04 0.59 0.90 0.67–1.20 0.48
0.94 0.80–1.11 0.49 1.12 0.99–1.27 0.07
1.08 0.39–3.07 0.89 0.55 0.11–2.70 0.47
0.66 0.28–1.55 0.34 0.78 0.12–5.19 0.79
0.84 0.28–2.53 0.76 2.41 0.71–8.14 0.16
2.37 0.97–5.77 0.06 0.63 0.12–3.38 0.59
1.62 0.67–3.89 0.28 6.30 1.36–29.14 0.02
1.66 0.38–7.26 0.50 5.28 1.59–17.57 0.007
ction fraction; eGFR: Estimated glomerular filtration rate; HDL: High density
Table 3 All-cause mortality in the study population distributed
into the three analyzed genotypes of the adiponectin genes
Females Males p-value
Adiponectin
C/C, n (%) 130/234 (55.6) 133/242 (55.0) p = 0.90
C/G, n (%) 84/234 (35.9) 96/242 (39.7) p = 0.40
G/G, n (%) 20/234 (8.5) 13/242 (17.8) p = 0.17
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preted with caution. No prognostic information could be
demonstrated in the male group (HR: 0.87; 95 % CI 0.47–
1.62; p = 0.66), and an interaction analysis supported the
gender difference reported (p = 0,000082).
A Kaplan-Meier analysis showed that C/C carriers of
the rs266729 gene exhibited higher cardiovascular mortal-
ity compared to the C/G or the G/G genotypes in the fe-
male group (Fig. 1). However, the sample size is limited.
Performing the corresponding analyses of the different
genotypes of rs266729 in the male group did not reveal
any significant differences between the three genotypes.
Discussion
Adiponectin and cardiovascular mortality
The protein adiponectin has a multifaceted action in the
body, including effects in the cardiovascular area. It is gen-
erally believed that adiponectin suppresses apoptosis, and
directly protects the cardiac cells from oxidative stress and
inflammation and finally from ischemic injuries [28]. The
complexity of actions of adiponectin is illustrated by the
fact that even if adiponectin have a cardiovascular protect-
ing effect [6], many epidemiological studies have shown
that high levels is associated with increased cardiovascularTable 4 Cox proportional hazard regression illustrating the risk of ca
allele of rs266729 SNP of adiponetin adjusted for well-known clinica
population during 80 months of follow-up
Variables Total population
Hazard ratio 95 % CI p-value
Age 1,13 1.05-1.22 0.002
Hypertension 1.34 0.71-2.51 0.36
IHD 1.15 0.63-2.10 0.64
BMI 0.98 0.92-1.05 0.60
CRP 1.0 0.94-1.06 0.90
b-glucose 1.12 0.96-1.32 0.16
HDL 0.68 0.33-1.40 0.29
eGFR<60mL/min 1.25 0.71-2.20 0.43
Hb<120g/L 1.18 0.57-2.45 0.65
EF<40 % 1.78 0.84-3.77 0.13
Rs266729 C/C vs. C/G or G/G 1.54 0.91-2.61 0.11
Note: BMI: Body mass index; CRP; C-reactive protein; eGFR: Estimated glomerular filmortality [9, 10, 29, 30]. The data we present gives support
for this observation with higher mortality in those with
high plasma level of of the SNP rs266729 of adiponectin.
Therefore, the hypothesis has been launched that a
healthy and a diseased population differs in pattern of
reaction on high levels of adiponectin [31], and there are
reports indicating a cardioprotective effect of high levels
of adiponectin in healthy individuals [32]. Furthermore,
in the literature there are reports indicating a gender dif-
ference in serum levels of adiponectin where the females
have higher levels compared to males [8, 30]. We could
corroborate this relation as we can report a highly sig-
nificant difference between the two genders with a
higher plasma level in the females.
We have evaluated the biologically active part of adipo-
nectin, the high molecular weight part. Even if the vast
majority of reports in the literature is on total adiponectin
measurements, the results regarding cardiovascular risk
evaluations can be compared, as reported by Karas et al.
[33]. We could demonstrate a more than 2 fold increased
risk of cardiovascular mortality if high levels of HMW-
adiponectin could be measured, even in competition with
NT-proBNP, and when adjusted for other well-known
clinical variables. Even if the confidence interval is wide,
the information that high levels of adiponectin is a signifi-
cant risk, is robust.
The golden standard of biomarkers in the handling of
heart failure is NT-proBNP, and in the literature there
are reports indicating a significant correlation between
NT-proBNP and plasma adiponectin in asymptomatic
older men [34]. Wannamethee et al. reported a correlation
coefficient of 0.16 (p < 0.0001) [34]. We could report the
same correlation coefficient in the correspondingrdiovascular mortality in the C/C allele versus the C/G or G/G
l risk factors influencing cardiovascular risk in an elderly
Males Females
Hazard ratio 95 % CI p-value Hazard ratio 95 % CI p-value
1.18 1.06-1.30 0.001 1.16 0.99-1.34 0.06
1.42 0.68-2.95 0.35 1.50 0.36-6.22 0.58
0.77 0.36-1.64 0.50 1.92 0.63-5.79 0.25
0.92 0.83-1.02 0.11 1.08 0.98-1.19 0.14
0.99 0.94-1.04 0.61 0.89 0.65-1.20 0.44
1.10 0.90-1.34 0.34 1.17 0.85-1.61 0.34
1.19 0.40-3.48 0.76 0.78 0.23-2.64 0.68
0.85 0.43-1.70 0.65 4.24 1.08–16.60 0.04
0.87 0.30-2.58 0.80 2.14 0.70-6.57 0.18
2.40 0.97-5.97 0.06 2.45 0.48-12.36 0.28
0.87 0.47-1.62 0.66 9.35 1.99-43.91 0.005
tration rate; EF: Ejection fraction; HDL; High density lipoprotein
Complete  Censored
 Adiponectin C/G and G/G
 Adiponectin C/C





























At start 20 months 40 months 60 months 80 months
Adiponectin
C/C, n 130 130 127 118 109
C/G or G/G, n 104 101 100 98 91
Note: n: number
Fig. 1 Cumulative proportion surviving from cardiovascular mortality as reflected by the adioponectin genotypes C/C vs. C/G or G/G in an elderly
female population followed during 80 months. Note: Censored participants were those still living at the end of the study period, or those who
had died for reasons other than cardiovascular disease. Completed participants were those who had died due to cardiovascular disease
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an even higher correlation coefficient in our female popu-
lation (r = 0.22; p = 0.008).
Genotypes of rs266729 and cardiovascular mortality
For the first time we have also investigated the distribution
and the prognostic information of the three genotypes
C/C, C/G and G/G of rs266729 SNP of adiponectin in
the same population as evaluated above. We could report
a higher cardiovascular risk for the C/C carrier compared
to the two other genotypes among the females, but not
among the males, even if the gender difference should be
interpreted with caution due to a small sample size. As
there are variables that are associated with the rs266729
SNP, as systolic blood pressure reported by Avery et al. we
have adjusted for hypertension in our multivariate evalua-
tions, and still could report the significant difference in
cardiovascular risk of the three genotypes in females [35].
As there is an association between b-glucose and adipo-
nectin, and between high density lipoprotein, adjustments
have also been done with these covariates. The result,
however, persisted.
The two genders have been evaluated regarding cardio-
vascular risk in those with high adiponectin concentration,
and the C/C carriers. Even after adjusting for multiple test-
ing using Bonferroni’s rule (multiplying the obtained Pvalue with the number of tests performed), there is still a
clear significance for the adjusted P value obtained in the
female group (p = 0.028 for the increased cardiovascular
risk in those with a adiponectin concentration in the 4th
quartile, and p = 0.002 for the increased cardiovascular risk
of the female C/C carriers in the multiple models).
The presented study has a limited sample size influ-
encing the obtained results of the statistical evalua-
tions. Therefore, it does not have power to exclude
that the male group also could have increased risk in
those with high adiponectin concentration, or are C/C
carriers, as could be seen from the relatively wide con-
fidence intervals of the obtained point estimate in the
multiple Cox regressions. However, the results pre-
sented indicate that for those with high adiponectin
levels, or for the C/C carriers an increased risk exist.
The obtained results are interesting, and as the cost for
the obtained genetic evaluations are not much higher than
that from biomarker analyses done in the clinical routine, it
could be suggested that this type of evaluation might help
the clinician to identify a group with increased cardiovascu-
lar risk when health resources are limited.
Limitations
The presented research is a community-based study, and
thus the majority of patients had discrete or no
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vascular disease (ischemic heart disease and/or hyper-
tension and/or diabetes and/or heart failure: were not in
the minority (419 out of 476: 88 %) and thus the size of
those with increased cardiac risk is significant. However,
the total study population was small which resulted in
wide confidence intervals in risk evaluations, thus mak-
ing the interpretation of these uncertain.
Also, the presented study population was an elderly
population, and therefore it was not possible to extrapolate
the obtained results into other age groups. Besides, this
population consists of an elderly Swedish population con-
sisting of only Caucasian participants. It is therefore not
possible to extrapolate the results into other ethnicities.
Also, due to the limited sample size the gender differ-
ences demonstrated should be regarded as hypothesis-
generating, and the interpretation should therefore be
drawn with caution, even if the interaction analysis point
to a specific gender difference.
Finally, as the subgroups of those with certain geno-
types are small, the results of some of the evaluations
should be interpreted with caution. The presented study
should therefore be regarded as hypothesis generating,
and should warrant for further research.Conclusion
Adiponectin is a protein that have complex functions
within the body. We present data indicating an association
between high plasma levels of adiponectin and increased
cardiovascular risk for elderly healthy persons, and there is
indications that there is a gender difference. We could also
present that in the same population the females with
the C/C carrier of the rs266729 SNP of adiponectin had
a significantly increased cardiovascular risk compared
to the C/G or the G/G carriers. No such a difference in
cardiovascular risk could be observed in the males.
We suggest that these data, as extracted from a rela-
tively small sample would be regarded as hypothesis-
generating, and to warrant further research in this
expanding area.
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